or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    JNJ C -0.40 3.21
    PRU C -0.36 2.72
    GDDY C 0.26 2.60
    TRV B 0.40 2.57
    PEP D -1.99 2.50
    AMP B -0.67 2.50
    BK A 0.14 2.43
    ABBV C -0.08 2.33
    KMB D 0.46 2.13
    MPC D -1.18 2.09

    Represented by ETF Holdings

    Keywords: S&P 500 Financial Products Infection Insurance Retail Outlets Annuity Products Disability Dow Jones Component Fixed Annuity Infection Prevention Infection Prevention Products Investment Management Pain Management Riversource Variable And Fixed Annuity Products Adalimumab Advanced Prostate Cancer Advisory Services Anemia Annuities
    Industries: Asset Management Drug Manufacturers - Major Beverages - Soft Drinks Household & Personal Products Insurance - Life Insurance - Property & Casualty Internet Content & Information Oil & Gas Refining & Marketing

    Recent News for Federated Hermes ETF Trust Federated Hermes MDT Large Cap Value ETF & its Holdings

    Date Stock Title
    Sep 21 JNJ Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits
    Sep 20 PEP Why PepsiCo Stock Lost Its Fizz on Friday
    Sep 20 JNJ J&J Unit Seeks Chapter 11 Bankruptcy for Third Time Over Baby Powder Suits
    Sep 20 JNJ J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
    Sep 20 JNJ Johnson & Johnson Boosts Talc Settlement Payment to $8 Billion in Unit's Bankruptcy Case
    Sep 20 JNJ Johnson & Johnson unit seeks third Chapter 11 bankruptcy filing to settle talc claims
    Sep 20 JNJ Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
    Sep 20 JNJ J&J unit files for bankruptcy to advance $10 billion talc settlement
    Sep 20 JNJ J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
    Sep 20 JNJ Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
    Sep 20 JNJ Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
    Sep 20 PEP Great investing debate: Growth or value stocks post-rate cuts?
    Sep 20 MPC MPLX LP (NYSE:MPLX): A Bull Case Theory
    Sep 20 BK Federal Reserve said to face resistance from FDIC on reworked bank capital plan
    Sep 20 PEP FedEx, PepsiCo downgraded: Wall Street's top analyst calls
    Sep 20 PEP Target, Home Depot And More On CNBC's 'Final Trades'
    Sep 20 PEP Why PepsiCo, Robert Half And Horace Mann Educators Are Winners For Passive Income
    Sep 20 PEP PepsiCo dips after Morgan Stanley pulls its bull rating
    Sep 20 PEP Why Target poached a top PepsiCo exec to be its new CFO
    Sep 20 ABBV AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
    The fund seeks to achieve its objective by investing primarily in the common stock of large-cap U.S. companies undervalued relative to the market. It will invest its assets so that at least 80% of its net assets (plus any borrowings for investment purposes) are invested in a mix of large-cap and value investments. The fund manager actively trades its portfolio securities in an attempt to achieve its investment objective.
    Index Fund Private Equity Investment Management Stock Fund
    Back to the Main FLCV Page...